Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma.
Zito Marino F, Morabito A, Gridelli C, Rocco G, Liguori G, De Rosa N, Botti G, Franco R. Zito Marino F, et al. Among authors: de rosa n. Appl Immunohistochem Mol Morphol. 2016 Oct;24(9):e86-e88. doi: 10.1097/PAI.0000000000000328. Appl Immunohistochem Mol Morphol. 2016. PMID: 26990744
Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.
Zito Marino F, Liguori G, Aquino G, La Mantia E, Bosari S, Ferrero S, Rosso L, Gaudioso G, De Rosa N, Scrima M, Martucci N, La Rocca A, Normanno N, Morabito A, Rocco G, Botti G, Franco R. Zito Marino F, et al. Among authors: de rosa n. PLoS One. 2015 Sep 30;10(9):e0139264. doi: 10.1371/journal.pone.0139264. eCollection 2015. PLoS One. 2015. PMID: 26422230 Free PMC article.
Aberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.
Scrima M, Zito Marino F, Oliveira DM, Marinaro C, La Mantia E, Rocco G, De Marco C, Malanga D, De Rosa N, Rizzuto A, Botti G, Franco R, Zoppoli P, Viglietto G. Scrima M, et al. Among authors: de marco c, de rosa n. J Cancer. 2017 Jan 15;8(2):227-239. doi: 10.7150/jca.17093. eCollection 2017. J Cancer. 2017. PMID: 28243327 Free PMC article.
Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.
Zito Marino F, Liguori G, Aquino G, La Mantia E, Bosari S, Ferrero S, Rosso L, Gaudioso G, De Rosa N, Scrima M, Martucci N, La Rocca A, Normanno N, Morabito A, Rocco G, Botti G, Franco R. Zito Marino F, et al. Among authors: de rosa n. PLoS One. 2015 Oct 21;10(10):e0141521. doi: 10.1371/journal.pone.0141521. eCollection 2015. PLoS One. 2015. PMID: 26488404 Free PMC article. No abstract available.
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Malapelle U, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, de Rosa N, Vitiello F, Russo S, Pepe F, Iaccarino A, Micheli P, Illiano A, Carlomagno C, Piantedosi FV, Troncone G. Malapelle U, et al. Among authors: de stefano a, de rosa n, de luca c. Cancer Cytopathol. 2013 Oct;121(10):552-60. doi: 10.1002/cncy.21322. Epub 2013 Jun 18. Cancer Cytopathol. 2013. PMID: 23780873 Free article.
135 results